Streetbeat News

Products Services

NTNX

NVDA

Nutanix and NVIDIA have announced a collaboration aimed at accelerating the adoption of AI in enterprise settings. This partnership will leverage Nutanix's cloud platform and NVIDIA's AI software and hardware to provide businesses with advanced AI capabilities.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:34 am

ANIX

Anixa Biosciences has started treating the fifth patient in its ovarian cancer CAR-T clinical trial, marking a significant milestone in the development of its innovative cancer therapy.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:33 am

SWI

SolarWinds has launched a new AI-driven platform aimed at transforming IT service management. This move is expected to enhance the company's product offerings and potentially increase its market share.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:33 am

JYD

Jayud has announced a new certification and the launch of its Longgang E-Commerce Operation Center, which is expected to enhance its operational capabilities and market presence.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:31 am

CTXR

Citius Pharmaceuticals shares are trading higher after the company's Phase 3 trial of Mino-Lok met primary and secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:30 am

PEP

TSLA

Tesla is delivering 50 more Semi trucks to PepsiCo, expanding PepsiCo's fleet to 86 Semis. Tesla is also building a high-volume Semi factory at Giga Nevada, with production for external customers starting in 2026.

Portfolio Pulse from Anan Ashraf

May 21, 2024 | 11:24 am

CYD

The first batch of green energy buses equipped with Yuchai Xingshunda hydrogen fuel cells has been launched. This development is significant for the green energy sector and highlights the advancements in hydrogen fuel cell technology.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:17 am

CTXR

Citius Pharmaceuticals announced that its Phase 3 trial of Mino-Lok met its primary endpoint, showing a statistically significant improvement in the time to failure event compared to the control arm patients receiving clinician-directed anti-infective lock solution.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:16 am

SABS

SAB Biotherapeutics has received FDA clearance for its IND application to proceed with a Phase 1 trial for SAB-142, a treatment for Type 1 Diabetes.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:16 am

AZN

AstraZeneca (NASDAQ: AZN) has announced an ambitious plan to increase its total revenue to $80 billion by 2030, up from $45.8 billion in 2023. The growth will be driven by expanding its oncology, biopharmaceuticals, and rare disease portfolios, and introducing 20 new medicines by the end of the decade. The company will also invest in transformative technologies and platforms to sustain growth beyond 2030. AstraZeneca aims to achieve a mid-30s percentage core operating margin by 2026 and maintain it post-2026. Analysts have mixed views on the revenue target, with some seeing a 20% upside to the 2030 consensus.

Portfolio Pulse from Vandana Singh

May 21, 2024 | 11:16 am